Single-center, Open-label, Randomized, Two-treatment, Single-dose, Crossover Study in Healthy Subjects to Investigate the Biocomparison of the Adult and Pediatric Formulation of Macitentan
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2016
At a glance
- Drugs Macitentan (Primary)
- Indications Eisenmenger complex; Glioblastoma; Pulmonary arterial hypertension
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 07 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 22 Sep 2015 Status changed from not yet recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 14 Aug 2015 According to the ClinicalTrials.gov record, planned initiation date changed from 1 Jul 2015 to 1 Aug 2015.